Company
Every published round LEO Pharma A/S took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies LEO Pharma A/S has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for LEO Pharma A/S, as distinct from the investments it has made.
Companies LEO Pharma A/S has backed that another company then bought. An exit for the holding, not a deal LEO Pharma A/S did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of LEO Pharma A/S is recorded as having been acquired. | ||||
Companies LEO Pharma A/S acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Peplin Inc | Acquisition | 3 Sep 2009 | ~$348.4m | GBS Ventures (3 Sep 2009), GBS Ventures (3 Sep 2009) |
| Peplin, Inc. | Acquisition | Sep 2009 | US$287.5m | GBS Ventures (25 May 2010), GBS Ventures (12 Nov 2009) |
| Name | Role | Sources |
|---|---|---|
| Gitte Aabo | President and CEO | GBS Ventures (12 Nov 2009), GBS Ventures (3 Sep 2009) |
Stories naming LEO Pharma A/S. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
LEO Pharma's acquisition of Peplin is done, a deal agreed in September 2009 for about US$287.5 million. Peplin continues as a LEO subsidiary led by chief executive George Mahaffey, keeping Australian operations.
Also GBS Ventures
Leo Pharma has agreed a US$287.5m cash takeover of Peplin, the ASX-listed skin-disease drug developer in GBS Ventures' portfolio; GBS recalls leading its late-2008 round alongside two American venture backers.
LEO Pharma has struck a deal to buy ASX-listed Peplin for roughly US$287.5 million, with its two biggest shareholders, including GBS Venture Partners, backing the transaction.
Also GBS Ventures